Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Micropep is a private French-American agricultural biotechnology company developing micropeptide-based products for sustainable crop protection and crop stimulation. Its core approach uses short natural peptides to regulate plant genes and proteins without modifying plant DNA, positioning the company as a developer of biological alternatives to conventional agrochemicals. Micropep’s proprietary KRISALIX discovery platform combines computational biology, artificial intelligence, bioproduction, and formulation technologies to identify, optimize, and manufacture peptide candidates at agricultural cost points. The company is advancing a pipeline spanning weed control, disease control, germination, flowering, and growth applications, and has stated that it is preparing for the commercial launch of its first micropeptide fungicide. Micropep operates from France with additional offices in the United States and collaborates with industry partners to bring peptide-based crop protection products to market.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Micropep.